Evidence Hub

Efficacy of Melatonin for Insomnia in Children with Autism Spectrum Disorder: A Meta-analysis

Xiong M, Li F, Liu Z, Xie X, Shen H, Li W, Wei L, He R

Neuropediatrics, 2023

238 participants · 23 citations

Abstract

Abstract Aim This study aimed to evaluate the effectiveness of melatonin in treating insomnia in children with autism spectrum disorder (ASD). Methods Comprehensive searches were conducted in the PubMed, EMBASE, and Web of Science databases from their inception to April 20, 2022. Data were extracted and assessed for quality by two researchers. Statistical analysis was performed using the Stata 15.0 software. Results Four studies including 238 patients were included. The results showed that compared with the control group, melatonin could shorten the sleep-onset latency (standardized mean difference [SMD] = − 1.34, 95% CI: −2.19 to −0.48), reduce the number of awakenings (SMD = -2.35, 95% CI: −4.62 to −0.08), and prolong the total sleep time (SMD = 1.42, 95% CI: 0.5–2.33) in children with ASD. Conclusion Melatonin has a certain effect on relieving sleep disturbances in children with ASD, which can shorten sleep latency, reduce the number of awakenings, and prolong total sleep time. Larger studies are required to verify this hypothesis.

How strong is the evidence?

Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 238 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free